Successful use of intravenous dexmedetomidine for magnetic resonance imaging sedation in autistic children

Sheikh Sohail Ahmed, Tamara Unland, James E. Slaven, Mara Nitu, Mark R. Rigby

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objectives: Autism and autism spectrum disorders (A/ASD) represent a family of neurodevelopmental conditions that are associated with overactive, difficult-to-control behaviors. Sedating these patients for magnetic resonance imaging (MRI) poses challenges. Children with A/ASD were examined against clinical controls to determine the effectiveness and safety of intravenous (IV) dexmedetomidine for deep sedation. Methods: The quality assurance data on all of the children who received IV dexmedetomidine sedation for MRI between July 2007 and December 2012 were reviewed. Patients in both groups were sedated by an intensivist-based team with a standard plan of 2 μg/kg IV dexmedetomidine administered for 10 minutes followed by an infusion of 1 μg I kg-1I hour-1. The amount of IV dexmedetomidine was titrated to the deep level of sedation. A total of 56 patients in the A/ASD group and 107 in the control group were sedated with no reported sedation failures. Sedation parameters were compared between the A/ASD and control groups using analysis of covariance models, controlling for age, sex, and weight. Results: Children in the A/ASD group were predominantly male (73%) and older (6.1 ± 0.3 years) than children in the control group (56%; 5.0 ± 0.2 years; P > 0.05 for both). Procedure time was significantly shorter for patients in the A/ASD group than in control patients (34.6 ± 2.4 vs 44.3 ± 1.6 minutes; P > 0.05). The A/ASD and control groups required a similar IV bolus of dexmedetomidine (2.6 μg/kg ± 0.1 vs 2.4 μg/kg ± 0.10; P = 0.29), with a significantly lower infusion dose in the A/ASD group (0.74 μg/kg ± 0.05 vs 0.89 7mu;g/kg ± 0.03; P > 0.05). Heart rates were similar in the A/ASD group and the control group (67.0 beats per minute ± 1.6 vs 69.3 ± 1.1 beats per minute; P = 0.250). There were no complications. Recovery time was approximately 7 minutes longer in the A/ASD group than in the control group, but this was nonsignificant (101.2 ± 3.5 minutes vs 94.2 ± 2.4 minutes; P = 0.12). Analyses were performed using analysis of covariancemethods and generalized linear models to control for age, sex, and weight. Conclusions: Children with A/ASD can be successfully sedated for MRIs with IV dexmedetomidine without complications.

Original languageEnglish
Pages (from-to)559-564
Number of pages6
JournalSouthern Medical Journal
Volume107
Issue number9
DOIs
StatePublished - 2014

Fingerprint

Dexmedetomidine
Autistic Disorder
Magnetic Resonance Imaging
Control Groups
Deep Sedation
Autism Spectrum Disorder
Weights and Measures
Behavior Control
Linear Models
Heart Rate

Keywords

  • Autistic spectrum disorders
  • Conscious sedation
  • Dexmedetomidine
  • Magnetic resonance imaging
  • Pediatrics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Successful use of intravenous dexmedetomidine for magnetic resonance imaging sedation in autistic children. / Ahmed, Sheikh Sohail; Unland, Tamara; Slaven, James E.; Nitu, Mara; Rigby, Mark R.

In: Southern Medical Journal, Vol. 107, No. 9, 2014, p. 559-564.

Research output: Contribution to journalArticle

Ahmed, Sheikh Sohail ; Unland, Tamara ; Slaven, James E. ; Nitu, Mara ; Rigby, Mark R. / Successful use of intravenous dexmedetomidine for magnetic resonance imaging sedation in autistic children. In: Southern Medical Journal. 2014 ; Vol. 107, No. 9. pp. 559-564.
@article{7ce87f23d9154f75989ee596a40909a7,
title = "Successful use of intravenous dexmedetomidine for magnetic resonance imaging sedation in autistic children",
abstract = "Objectives: Autism and autism spectrum disorders (A/ASD) represent a family of neurodevelopmental conditions that are associated with overactive, difficult-to-control behaviors. Sedating these patients for magnetic resonance imaging (MRI) poses challenges. Children with A/ASD were examined against clinical controls to determine the effectiveness and safety of intravenous (IV) dexmedetomidine for deep sedation. Methods: The quality assurance data on all of the children who received IV dexmedetomidine sedation for MRI between July 2007 and December 2012 were reviewed. Patients in both groups were sedated by an intensivist-based team with a standard plan of 2 μg/kg IV dexmedetomidine administered for 10 minutes followed by an infusion of 1 μg I kg-1I hour-1. The amount of IV dexmedetomidine was titrated to the deep level of sedation. A total of 56 patients in the A/ASD group and 107 in the control group were sedated with no reported sedation failures. Sedation parameters were compared between the A/ASD and control groups using analysis of covariance models, controlling for age, sex, and weight. Results: Children in the A/ASD group were predominantly male (73{\%}) and older (6.1 ± 0.3 years) than children in the control group (56{\%}; 5.0 ± 0.2 years; P > 0.05 for both). Procedure time was significantly shorter for patients in the A/ASD group than in control patients (34.6 ± 2.4 vs 44.3 ± 1.6 minutes; P > 0.05). The A/ASD and control groups required a similar IV bolus of dexmedetomidine (2.6 μg/kg ± 0.1 vs 2.4 μg/kg ± 0.10; P = 0.29), with a significantly lower infusion dose in the A/ASD group (0.74 μg/kg ± 0.05 vs 0.89 7mu;g/kg ± 0.03; P > 0.05). Heart rates were similar in the A/ASD group and the control group (67.0 beats per minute ± 1.6 vs 69.3 ± 1.1 beats per minute; P = 0.250). There were no complications. Recovery time was approximately 7 minutes longer in the A/ASD group than in the control group, but this was nonsignificant (101.2 ± 3.5 minutes vs 94.2 ± 2.4 minutes; P = 0.12). Analyses were performed using analysis of covariancemethods and generalized linear models to control for age, sex, and weight. Conclusions: Children with A/ASD can be successfully sedated for MRIs with IV dexmedetomidine without complications.",
keywords = "Autistic spectrum disorders, Conscious sedation, Dexmedetomidine, Magnetic resonance imaging, Pediatrics",
author = "Ahmed, {Sheikh Sohail} and Tamara Unland and Slaven, {James E.} and Mara Nitu and Rigby, {Mark R.}",
year = "2014",
doi = "10.14423/SMJ.0000000000000160",
language = "English",
volume = "107",
pages = "559--564",
journal = "Southern Medical Journal",
issn = "0038-4348",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Successful use of intravenous dexmedetomidine for magnetic resonance imaging sedation in autistic children

AU - Ahmed, Sheikh Sohail

AU - Unland, Tamara

AU - Slaven, James E.

AU - Nitu, Mara

AU - Rigby, Mark R.

PY - 2014

Y1 - 2014

N2 - Objectives: Autism and autism spectrum disorders (A/ASD) represent a family of neurodevelopmental conditions that are associated with overactive, difficult-to-control behaviors. Sedating these patients for magnetic resonance imaging (MRI) poses challenges. Children with A/ASD were examined against clinical controls to determine the effectiveness and safety of intravenous (IV) dexmedetomidine for deep sedation. Methods: The quality assurance data on all of the children who received IV dexmedetomidine sedation for MRI between July 2007 and December 2012 were reviewed. Patients in both groups were sedated by an intensivist-based team with a standard plan of 2 μg/kg IV dexmedetomidine administered for 10 minutes followed by an infusion of 1 μg I kg-1I hour-1. The amount of IV dexmedetomidine was titrated to the deep level of sedation. A total of 56 patients in the A/ASD group and 107 in the control group were sedated with no reported sedation failures. Sedation parameters were compared between the A/ASD and control groups using analysis of covariance models, controlling for age, sex, and weight. Results: Children in the A/ASD group were predominantly male (73%) and older (6.1 ± 0.3 years) than children in the control group (56%; 5.0 ± 0.2 years; P > 0.05 for both). Procedure time was significantly shorter for patients in the A/ASD group than in control patients (34.6 ± 2.4 vs 44.3 ± 1.6 minutes; P > 0.05). The A/ASD and control groups required a similar IV bolus of dexmedetomidine (2.6 μg/kg ± 0.1 vs 2.4 μg/kg ± 0.10; P = 0.29), with a significantly lower infusion dose in the A/ASD group (0.74 μg/kg ± 0.05 vs 0.89 7mu;g/kg ± 0.03; P > 0.05). Heart rates were similar in the A/ASD group and the control group (67.0 beats per minute ± 1.6 vs 69.3 ± 1.1 beats per minute; P = 0.250). There were no complications. Recovery time was approximately 7 minutes longer in the A/ASD group than in the control group, but this was nonsignificant (101.2 ± 3.5 minutes vs 94.2 ± 2.4 minutes; P = 0.12). Analyses were performed using analysis of covariancemethods and generalized linear models to control for age, sex, and weight. Conclusions: Children with A/ASD can be successfully sedated for MRIs with IV dexmedetomidine without complications.

AB - Objectives: Autism and autism spectrum disorders (A/ASD) represent a family of neurodevelopmental conditions that are associated with overactive, difficult-to-control behaviors. Sedating these patients for magnetic resonance imaging (MRI) poses challenges. Children with A/ASD were examined against clinical controls to determine the effectiveness and safety of intravenous (IV) dexmedetomidine for deep sedation. Methods: The quality assurance data on all of the children who received IV dexmedetomidine sedation for MRI between July 2007 and December 2012 were reviewed. Patients in both groups were sedated by an intensivist-based team with a standard plan of 2 μg/kg IV dexmedetomidine administered for 10 minutes followed by an infusion of 1 μg I kg-1I hour-1. The amount of IV dexmedetomidine was titrated to the deep level of sedation. A total of 56 patients in the A/ASD group and 107 in the control group were sedated with no reported sedation failures. Sedation parameters were compared between the A/ASD and control groups using analysis of covariance models, controlling for age, sex, and weight. Results: Children in the A/ASD group were predominantly male (73%) and older (6.1 ± 0.3 years) than children in the control group (56%; 5.0 ± 0.2 years; P > 0.05 for both). Procedure time was significantly shorter for patients in the A/ASD group than in control patients (34.6 ± 2.4 vs 44.3 ± 1.6 minutes; P > 0.05). The A/ASD and control groups required a similar IV bolus of dexmedetomidine (2.6 μg/kg ± 0.1 vs 2.4 μg/kg ± 0.10; P = 0.29), with a significantly lower infusion dose in the A/ASD group (0.74 μg/kg ± 0.05 vs 0.89 7mu;g/kg ± 0.03; P > 0.05). Heart rates were similar in the A/ASD group and the control group (67.0 beats per minute ± 1.6 vs 69.3 ± 1.1 beats per minute; P = 0.250). There were no complications. Recovery time was approximately 7 minutes longer in the A/ASD group than in the control group, but this was nonsignificant (101.2 ± 3.5 minutes vs 94.2 ± 2.4 minutes; P = 0.12). Analyses were performed using analysis of covariancemethods and generalized linear models to control for age, sex, and weight. Conclusions: Children with A/ASD can be successfully sedated for MRIs with IV dexmedetomidine without complications.

KW - Autistic spectrum disorders

KW - Conscious sedation

KW - Dexmedetomidine

KW - Magnetic resonance imaging

KW - Pediatrics

UR - http://www.scopus.com/inward/record.url?scp=84908266689&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908266689&partnerID=8YFLogxK

U2 - 10.14423/SMJ.0000000000000160

DO - 10.14423/SMJ.0000000000000160

M3 - Article

VL - 107

SP - 559

EP - 564

JO - Southern Medical Journal

JF - Southern Medical Journal

SN - 0038-4348

IS - 9

ER -